Characteristics of patients who received chemotherapy and patients who declined chemotherapy
| Received chemo | Declined chemo | p | |
|---|---|---|---|
| Total (n = 139) | 93 (66.9) | 46 (33.1) | |
| Gender, n (%) Male Female | 83 (89.2) 10 (10.8) | 35 (76.1) 11 (23.9) | 0.041 |
| Laterality, n (%) Right Left | 54 (58.1) 39 (41.9) | 27 (58.7) 19 (41.3) | 0.943 |
| Age, mean (SD) | 68.4 (6.36) | 74.4 (7.35) | <0.001 |
| Performance status, n (%) 0 1 2 | 40 (43.0) 48 (51.6) 5 (5.4) | 8 (17.4) 32 (69.6) 6 (13.0) | 0.005 |
| Histology, n (%) Epithelioid Sarcomatoid Biphasic Desmoplastic Not specified | 63 (67.7) 15 (16.1) 9 (9.7) 2 (2.2) 4 (4.3) | 36 (78.3) 6 (13.0) 1 (2.2) 1 (2.2) 2 (4.3) | 0.540 |
| IMIG stage, n (%) I II III IV Not documented | 28 (30.1) 4 (4.3) 33 (35.5) 16 (17.2) 12 (12.9) | 15 (32.6) 2 (4.3) 13 (28.2) 8 (17.4) 8 (17.4) | 0.587 |
| Symptoms, n (%) Asymptomatic Chest pain Breathlessness Cough Systemic symptoms (fatigue, weight loss or sweats) | 6 (6.5) 37 (41.9) 76 (81.7) 41 (44.1) 38 (41.3) | 0 (0) 22 (47.8) 39 (84.8) 18 (39.1) 22 (47.8) | 0.078 0.470 0.550 0.499 0.367 |
| Blood tests, median (IQR) Haemoglobin, g/dL, Neutrophils, x109/L Lymphocytes,x109/L Albumin, g/L NLR | 138 (126–150) 5.73 (4.80–7.00) 1.6 (1.15–2.15) 35 (31–38) 4.00 (2.73–5.38) | 132.5 (121–149) 5.84 (4.28–7.00) 1.32 (1.00–1.94) 34 (30–38) 4.18 (3.09–6.38) | 0.263 0.729 0.076 0.456 0.255 |
| Survival, days, median (IQR) HR (univariable cox proportional hazards) HR (multivariable cox proportional hazards) | 426 (290–674) 0.497 0.519 | 203 (126–405) | 0.001 0.001 0.015 |